Why in news
The Truenat platform, a rapid molecular test for the diagnosis of pulmonary, extrapulmonary, and rifampicin-resistant tuberculosis, that was developed in India, has been hailed for its role in combating TB and as a possible component of global healthcare solutions at the recently held 77th World Health Assembly in Geneva.
Truenat
Developed by Goa-based Molbio, a point-of-care molecular diagnostics company, Truenat was first launched in 2017 and is a real-time quantitative micro-PCR system.
It is a portable, battery-operated machine that can be deployed at labs, health centres, and in the field.
Truenat delivers results from samples in less than an hour and can test for over 40 diseases
TrueNat is used at over 7,000 primary health centres and community health centres under the National TB Elimination Programme
COMMENTS